These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30914433)

  • 1. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
    Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
    Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    Wen WX; Leong CO
    PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
    Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    Lai Z; Brosnan M; Sokol ES; Xie M; Dry JR; Harrington EA; Barrett JC; Hodgson D
    BMC Cancer; 2022 Jan; 22(1):13. PubMed ID: 34979999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
    Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
    Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biallelic
    Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
    JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Kraya AA; Maxwell KN; Eiva MA; Wubbenhorst B; Pluta J; Feldman M; Nayak A; Powell DJ; Domchek SM; Vonderheide RH; Nathanson KL
    JCO Precis Oncol; 2022 Feb; 6():e2100159. PubMed ID: 35201851
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
    Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
    [No Abstract]   [Full Text] [Related]  

  • 13. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    Mutter RW; Riaz N; Ng CK; Delsite R; Piscuoglio S; Edelweiss M; Martelotto LG; Sakr RA; King TA; Giri DD; Drobnjak M; Brogi E; Bindra R; Bernheim G; Lim RS; Blecua P; Desrichard A; Higginson D; Towers R; Jiang R; Lee W; Weigelt B; Reis-Filho JS; Powell SN
    J Pathol; 2017 Jun; 242(2):165-177. PubMed ID: 28299801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    Min A; Kim K; Jeong K; Choi S; Kim S; Suh KJ; Lee KH; Kim S; Im SA
    Sci Rep; 2020 Jul; 10(1):12506. PubMed ID: 32719318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
    J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
    Sztupinszki Z; Diossy M; Krzystanek M; Borcsok J; Pomerantz MM; Tisza V; Spisak S; Rusz O; Csabai I; Freedman ML; Szallasi Z
    Clin Cancer Res; 2020 Jun; 26(11):2673-2680. PubMed ID: 32071115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and epigenomic
    Menghi F; Banda K; Kumar P; Straub R; Dobrolecki L; Rodriguez IV; Yost SE; Chandok H; Radke MR; Somlo G; Yuan Y; Lewis MT; Swisher EM; Liu ET
    Sci Transl Med; 2022 Jul; 14(652):eabn1926. PubMed ID: 35857626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.